Retatrutide Drug Interactions: Complete Reference
Retatrutide is a triple agonist (GLP-1/GIP/glucagon) that interacts with the body through unique mechanisms, and understanding how it interfaces with other medications is essential for safe use. While retatrutide has few direct pharmacokinetic drug-drug interactions, its effects on gastric emptying, blood sugar, blood pressure, body weight, and appetite create indirect interactions that require attention. This comprehensive reference covers every major medication class (Jastreboff et al., NEJM 2023).
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Always disclose all medications to your healthcare provider before starting any new treatment. Never adjust medications without medical guidance.
Key Interaction Mechanisms
Before reviewing specific medications, understanding the three main ways retatrutide can affect other drugs helps put individual interactions in context:
- Delayed gastric emptying: Retatrutide's GLP-1 activity slows stomach emptying, potentially delaying or reducing absorption of oral medications. This is the most clinically relevant class effect.
- Metabolic improvement: Dramatic weight loss and improved insulin sensitivity can change the dose requirements of diabetes, blood pressure, and cholesterol medications.
- GI side effects: Nausea, vomiting, and diarrhea can affect oral medication absorption and cause dehydration that alters drug concentrations.
Complete Drug Interaction Reference
Diabetes Medications
| Medication | Interaction Level | Key Concern | Action |
|---|---|---|---|
| Metformin | Low | Additive GI effects | Safe; use XR formulation |
| Insulin (all types) | High | Hypoglycemia risk | Reduce insulin proactively; monitor BG closely |
| Sulfonylureas (glipizide, glimepiride) | High | Hypoglycemia risk | Reduce dose or discontinue; monitor BG |
| SGLT2 inhibitors (Jardiance, Farxiga) | Moderate | Additive dehydration risk | Ensure hydration; monitor kidney function |
| DPP-4 inhibitors (Januvia) | Low | Redundant GLP-1 pathway | Usually discontinued; no safety concern |
| Other GLP-1 RAs (semaglutide, tirzepatide) | Contraindicated | Overlapping mechanism | Do not combine; switch, do not stack |
| TZDs (pioglitazone) | Low-Moderate | Fluid retention | Monitor for edema; dose may need adjustment |
Cardiovascular Medications
| Medication | Interaction Level | Key Concern | Action |
|---|---|---|---|
| ACE inhibitors / ARBs | Low | Hypotension with weight loss | Monitor BP; reduce dose as weight drops |
| Beta-blockers | Low | Opposing heart rate effects | Monitor BP and HR; adjust as needed |
| Calcium channel blockers | Low | Hypotension with weight loss | Monitor BP; reduce dose as weight drops |
| Diuretics | Moderate | Dehydration, electrolyte imbalance | Monitor electrolytes; ensure hydration |
| Statins | Low | None significant | Continue; reassess lipids after weight loss |
| Warfarin | Moderate-High | INR changes from diet/weight shifts | Frequent INR monitoring |
| DOACs (Eliquis, Xarelto) | Low-Moderate | Absorption; weight-based dosing | Monitor if weight drops below 60 kg |
Thyroid Medications
| Medication | Interaction Level | Key Concern | Action |
|---|---|---|---|
| Levothyroxine (Synthroid) | Moderate | Delayed absorption; weight-based dosing | Take on empty stomach; extend wait to 60 min; check TSH q6-8wk |
| Methimazole / PTU | Low | Minimal | Continue; monitor thyroid levels |
Mental Health Medications
| Medication | Interaction Level | Key Concern | Action |
|---|---|---|---|
| SSRIs (sertraline, fluoxetine, etc.) | Low | Some cause weight gain | Continue; consider weight-neutral options |
| SNRIs (venlafaxine, duloxetine) | Low | Minimal | Continue as prescribed |
| Bupropion (Wellbutrin) | Low | Synergistic weight loss | Safe combination; potentially beneficial |
| Mirtazapine (Remeron) | Low | Significant weight gain | Discuss alternatives with psychiatrist |
| Antipsychotics (olanzapine, quetiapine) | Moderate | Weight gain; metabolic effects | Monitor metabolic parameters; may offset weight loss |
| Lithium | Moderate | Narrow therapeutic window; dehydration risk | Monitor lithium levels; ensure hydration |
Hormones and Contraceptives
| Medication | Interaction Level | Key Concern | Action |
|---|---|---|---|
| Oral contraceptives | Moderate-High | Reduced absorption | Use backup method or switch to non-oral |
| Non-oral contraceptives (IUD, implant, patch) | None | Not affected | Continue as normal |
| Testosterone | Low | Weight loss may improve natural levels | Monitor levels; may need dose adjustment |
| HRT (estrogen/progesterone) | Low | Oral forms may have delayed absorption | Consider transdermal if on oral HRT |
Pain Medications
| Medication | Interaction Level | Key Concern | Action |
|---|---|---|---|
| Acetaminophen (Tylenol) | Low | Delayed onset | Safe; preferred pain reliever |
| NSAIDs (ibuprofen, naproxen) | Moderate | Additive GI irritation; kidney risk | Limit use; take with food; stay hydrated |
| Opioids | Moderate | Additive GI slowing; constipation | Monitor for severe constipation; delayed absorption |
| Gabapentin / Pregabalin | Low | Weight gain potential | May partially offset weight loss; continue if needed |
Other Common Medications
| Medication | Interaction Level | Key Concern | Action |
|---|---|---|---|
| PPIs (omeprazole, pantoprazole) | Low | May help GI symptoms | Safe; may be beneficial |
| Antibiotics | Low | Delayed absorption timing | Continue as prescribed; monitor for vomiting |
| Oral steroids (prednisone) | Moderate | Raises blood sugar; causes weight gain | Monitor BG closely; may offset retatrutide benefits |
| Supplements (vitamins, minerals) | Low | Delayed absorption | Take consistently; monitor B12, vitamin D |
General Principles for All Oral Medications
- Delayed absorption: All oral medications may be absorbed more slowly due to delayed gastric emptying. For most medications, this changes timing but not total absorption.
- Narrow therapeutic index drugs (warfarin, lithium, digoxin, phenytoin, cyclosporine) require enhanced monitoring when starting retatrutide.
- Vomiting: If you vomit within 1-2 hours of taking an oral medication, it may not have been absorbed. Contact your provider for guidance.
- Weight-based medications: Any drug dosed by weight may need adjustment as body weight changes significantly.
- Dehydration-sensitive drugs: Ensure adequate hydration with medications that affect kidney function or are renally excreted.
GLP-1 Treatment With Medication Coordination
Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with comprehensive medical oversight that includes reviewing your complete medication list for interactions. Learn how Trimi works.
Frequently Asked Questions
Does retatrutide interact with most medications?
Retatrutide has few direct drug-drug interactions. The primary concerns are indirect: delayed absorption of oral medications, additive hypoglycemia risk with diabetes drugs, and dose requirement changes as weight drops. Most medications can be safely continued.
What medications should I never take with retatrutide?
The main contraindication is other GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide). Do not stack GLP-1 medications. All other drug classes can generally be combined with appropriate monitoring.
Should I take my medications at a different time?
For most medications, no timing changes are needed. Exceptions include levothyroxine (extend empty-stomach wait to 60 minutes) and oral contraceptives (consider non-oral alternatives). Take all medications consistently regardless of retatrutide injection day.
How do I know if a medication interaction is causing problems?
Watch for unexpected changes in blood sugar, blood pressure, heart rate, mood, pain control, or bleeding. Report any new symptoms to your provider, especially during the first few months of retatrutide treatment or after dose escalations.
More on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).